NKE
NIKE, Inc.
NKE has the edge over THRM overall, supported by stronger valuation and stronger modeled upside.
THRM
Gentherm Incorporated
THRM trails on the overall score without a compensating advantage in the available component scores.
NKE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
NKE's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
THRM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Healthy |
THRM's balance sheet is currently healthy, and its revenue and profitability are stable, but its cash flow is under pressure.
NKE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $37.76 | — |
| Cheap | 23x | $47.70 | +26% |
| Forward | 30x | $37.76 | — |
| Fair | 33x | $68.16 | +80% |
| Expensive | 47x | $97.86 | +159% |
Historical ranges are pointers, not guarantees.
NKE has the edge over THRM in the historical PE scenario, which offers more potential upside but is not a forecast.
THRM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $28.79 | — |
| Cheap | 24x | $6.79 | -76% |
| Fair | 36x | $10.21 | -65% |
| Expensive | 62x | $17.38 | -40% |
| Current | 103x | $28.79 | — |
Historical ranges are pointers, not guarantees.
THRM's PE is in its expensive range at 103x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
NKE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Stable | |
| Decline | |
| Improving | |
| Moderate | |
| Low |
Analysts expect NKE's profitability to improve, but its revenue to decline. However, they disagree widely on these estimates.
THRM Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for THRM, but weaker profitability. However, they disagree widely on these estimates.
NKE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.27 | -39% |
| Q3 2026 | $2.09 | +7.2% |
| Q2 2026 | $2.10 | -2.8% |
| Q1 2026 | $1.51 | -50% |
| Q4 2025 | $1.70 | -48% |
| Q3 2025 | $1.95 | -44% |
| Q2 2025 | $2.16 | -42% |
| Q1 2025 | $3.01 | -11% |
| Q4 2024 | $3.24 | -5.3% |
NKE's earnings per share have fallen from their peak: $2.09 over the past year, against $3.82 in late 2021.
THRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.82 | +907% |
| Q3 2026 | $0.28 | -72% |
| Q2 2026 | $0.85 | -16% |
| Q1 2026 | $0.73 | -54% |
| Q4 2025 | $0.59 | -71% |
| Q3 2025 | $0.99 | -54% |
| Q2 2025 | $1.01 | -52% |
| Q1 2025 | $1.59 | +9.7% |
| Q4 2024 | $2.06 | +69% |
THRM's earnings per share have fallen from their peak: $0.28 over the past year, against $3.50 in mid-2021.
NKE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.2B | -4.3% |
| Q2 2026 | $11B | -1.1% |
| Q1 2026 | $11.3B | +0.1% |
| Q4 2025 | $12.4B | +0.6% |
| Q3 2025 | $11.7B | +1.1% |
| Q2 2025 | $11.1B | -12% |
| Q1 2025 | $11.3B | -9.3% |
| Q4 2024 | $12.4B | -7.7% |
NKE's revenue fell from its 2023 peak and has held roughly level since: $11.2B last quarter, down 4.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.2% | +0.3 points |
| Q2 2026 | 12% | +9.2 points |
| Q1 2026 | 5.8% | -1.7 points |
| Q4 2025 | 8% | -3.4 points |
| Q3 2025 | 7.9% | -3.4 points |
| Q2 2025 | 2.9% | -11 points |
| Q1 2025 | 7.5% | -3.8 points |
| Q4 2024 | 11% | -2.9 points |
NKE has the edge over THRM on profitability, with a higher operating margin.
THRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $405.1M | +4.7% |
| Q2 2026 | $416.2M | +11% |
| Q1 2026 | $393.7M | +11% |
| Q4 2025 | $382.8M | +8.5% |
| Q3 2025 | $386.9M | +4.1% |
| Q2 2025 | $375.1M | -0.2% |
| Q1 2025 | $353.9M | -0.6% |
| Q4 2024 | $352.9M | -3.8% |
THRM has the edge over NKE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | -2.6 points |
| Q2 2026 | 2.6% | -3.8 points |
| Q1 2026 | 2.9% | -2 points |
| Q4 2025 | 4.6% | -2.1 points |
| Q3 2025 | 6.2% | -2.5 points |
| Q2 2025 | 6.4% | -2.4 points |
| Q1 2025 | 4.8% | -0.3 points |
| Q4 2024 | 6.7% | -1.9 points |
THRM's operating margin was 3.5% last quarter, down 2.6 points from the same quarter a year ago.
NKE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$64M | -527% |
| Q2 2026 | $1.5B | +313% |
| Q1 2026 | $284M | -83% |
| Q4 2025 | $386M | -58% |
| Q3 2025 | $15M | -95% |
| Q2 2025 | $363M | -85% |
| Q1 2025 | $1.7B | -11% |
| Q4 2024 | $920M | -65% |
NKE usually generates cash, though not every quarter: the latest was −$64M, but it generated $2.1B over the past year.
THRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.4M | -45% |
| Q2 2026 | -$1.2M | -103% |
| Q1 2026 | -$10.7M | +$17.5M |
| Q4 2025 | $6.7M | -51% |
| Q3 2025 | $46.5M | +75% |
| Q2 2025 | $36.2M | +104% |
| Q1 2025 | -$28.2M | -$6.6M |
| Q4 2024 | $13.6M | -52% |
THRM has the edge over NKE on cash flow, with more consistent year-over-year improvement.
NKE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +3.2M shares |
| 1 year | +0.4% | +5.2M shares |
| 3 years | -3.8% | -59.1M shares |
| 5 years | -8.4% | -135M shares |
| Available history | -6.9% | -110M shares |
NKE has 1.5B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $20M |
| Q3 2025 | $126M |
| Q2 2025 | $199M |
| Q1 2025 | $506M |
| Q4 2024 | $1.1B |
NKE has spent almost nothing on buybacks in the past year.
THRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -382K shares |
| 1 year | -0.2% | -76K shares |
| 3 years | -7.6% | -2.5M shares |
| 5 years | -8.7% | -2.9M shares |
| Available history | -7.9% | -2.6M shares |
THRM has the edge over NKE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $10M |
| Q1 2025 | — |
| Q4 2024 | $10M |
| Q3 2024 | $19.9M |
| Q4 2023 | $60M |
| Q3 2023 | $11.1M |
NKE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.2x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | 0.2x | Very low |
| Q3 2024 | 0.1x | Very low |
| Q2 2024 | -0.1x | Net Cash |
| Q1 2024 | -0.0x | Very low |
| Q4 2023 | 0.1x | Very low |
NKE has the edge over THRM on leverage, with a lower net debt burden relative to earnings.
THRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.6x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.5x | Very low |
THRM's net debt is less than a year of its operating earnings (EBITDA).
NKE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.0 | Neutral |
| Stochastic | 57.5 | Neutral |
NKE's weekly RSI is 40 (neutral) and its Stochastic is 58 (neutral).
THRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 23.1 | Neutral |
THRM's weekly RSI is 38 (neutral) and its Stochastic is 23 (neutral).
NKE PE vs Consumer Cyclical Sector
| Metric | NKE | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 18x | 0.3% above |
| PE % | 2 | 47 | 45 pts below |
NKE has the edge over THRM on valuation relative to its sector.
THRM PE vs Consumer Cyclical Sector
| Metric | THRM | Sector median | Relative |
|---|---|---|---|
| PE | 103x | 18x | 471% above |
| PE % | 96 | 47 | 49 pts above |
THRM is trading at 103x earnings, a 471% premium to the Consumer Cyclical sector's median of 18x.
NKE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.7 | 2.8% above |
| 20 week MA | $39.2 | 3.6% below |
| 50 week MA | $48.0 | 21% below |
| 100 week MA | $58.4 | 35% below |
| 200 week MA | $79.2 | 52% below |
NKE has the edge over THRM on trend strength, trading above more of its moving averages.
THRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $30.4 | 5.2% below |
| 20 week MA | $35.7 | 19% below |
| 50 week MA | $34.1 | 16% below |
| 100 week MA | $33.4 | 14% below |
| 200 week MA | $43.3 | 33% below |
THRM is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
NKE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $101.6 | $141.6 | +39% |
| 2021 | $141.6 | $165.7 | +17% |
| 2022 | $165.7 | $116.3 | -30% |
| 2023 | $116.3 | $108.6 | -6.6% |
| 2024 | $108.6 | $76.4 | -30% |
| 2025 | $76.4 | $60.9 | -20% |
| 2026 YTD | $60.9 | $37.8 | -38% |
NKE has finished four years in a row lower, and it's down 38% so far in 2026.
THRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.3 | $66.0 | +49% |
| 2021 | $66.0 | $82.4 | +25% |
| 2022 | $82.4 | $63.8 | -23% |
| 2023 | $63.8 | $52.4 | -18% |
| 2024 | $52.4 | $39.0 | -25% |
| 2025 | $39.0 | $37.2 | -4.7% |
| 2026 YTD | $37.2 | $28.8 | -23% |
THRM has the edge over NKE on returns for 2026, with the stronger performance.